Cancer Archives

News and Trends 20 Oct 2022

Spanish research institution to use Elicera Therapeutics’ iTANK platform

Elicera Therapeutics AB has entered a material transfer agreement with the Josep Carreras Leukaemia Research Institute (JCLRI) in Spain for use of the iTANK platform in arming CAR T-cells for the treatment of Ewing Sarcoma. Sweden’s Elicera is a clinical stage cell and gene therapy company developing next generation immuno-oncological treatments based on enhanced oncolytic […]

October 20, 2022 - 3 minutesmins - By Jim Cornall

brain cancer glioblastoma divide and conquer

News and Trends 20 Oct 2022

Healthy volunteer study for tablet to treat brain cancer open for recruitment

A clinical stage drug company developing sulforaphane-based medicines for cancer treatment has started recruiting for a pharmacokinetic / pharmacodynamic trial in healthy volunteers (HV). Evgen Pharma plc also announced the start an investigator sponsored clinical study (ISS) for a glioblastoma program. The purpose of the HV study is to examine the performance of Evgen’s new […]

October 20, 2022 - 4 minutesmins - By Liza Laws

News and Trends 20 Oct 2022

Enhanc3D Genomics raises £10M to advance technology platform

Enhanc3D Genomics, a functional genomics company, has raised £10 million ($11.2 million) in series A financing. The funds will be used to accelerate the development of its proprietary technology platform – GenLink3D. The financing was led by BGF and Parkwalk Advisors, with support from existing private investors and Bioqube Ventures. The funding will enable Enhanc3D […]

October 20, 2022 - 2 minutesmins - By Jim Cornall

News and Trends 20 Oct 2022

License from Helmholtz Munich will enable progression of brain cancer treatment

A treatment for one of the most aggressive and difficult to treat cancers is the focus of a licensing option that has been executed by Isotope Technologies Munich SE (ITM). The license from Helmholtz Munich was announced yesterday (October 19). The targeted radionuclide therapy with ITM-31 targets a specific protein (antigen) called CA XII, which […]

October 20, 2022 - 3 minutesmins - By Liza Laws

Anastasiia Slynko neobe therapeutics cancer

Startup Scout 19 Oct 2022

Neobe Therapeutics breaks down tumor defenses with bacteria

Many cancer patients cannot benefit from cancer immunotherapy because their tumors are protected from the immune system. Neobe Therapeutics’ bacterial therapy is designed to strip the tumors of their protective barriers. The immune system is very good at fighting tumors, and cancer immunotherapies are often able to supercharge our natural defenses to great effect. However, […]

October 19, 2022 - 4 minutesmins - By Jonathan Smith

News and Trends 19 Oct 2022

Report says 20% of global cancer deaths could be avoided

A new study by members of the Bloomberg New Economy International Cancer Coalition says at least 1.5 million deaths from cancer could be avoided each year. This is 20% of the annual global deaths resulting from cancer. The study says this could happen if international regulations around patient trials were more standardized and people placed […]

October 19, 2022 - 6 minutesmins - By Jim Cornall

News and Trends 19 Oct 2022

Domain Therapeutics to start clinical trials of solid tumor treatment

Domain Therapeutics says its immuno-oncology candidate has been cleared in Belgium and France, leading to a phase I clinical trial. It has cleared its clinical trial applications with the ANSM (Agence Nationale de Sécurité du Médicament et des produits de santé) in France and the AFMPS (Agence Fédérale des Médicaments et des Produits de Santé) […]

October 19, 2022 - 2 minutesmins - By Jim Cornall

News and Trends 17 Oct 2022

Gene activity could help identify risk of kidney cancer spreading

Among patients with kidney cancer, the activity of four specific genes in the cancer cells seems to be able to predict the risk of the tumor spreading and the patient’s chances of survival. This is shown by researchers from Karolinska Institutet (KI) in Sweden in a preclinical study published in Nature Communications. “This could potentially […]

October 17, 2022 - 4 minutesmins - By Jim Cornall

More News! 17 Oct 2022

Clinical trial of treatment for advanced solid tumors approved

A clinical trial of a drug to treat advanced solid tumors has been approved by the National Medical Products Administration. China-based Akeso Inc., made the announcement on Sunday (October 16) about a phase 1b/2 clinical trial of its in-house developed Ivonescimab (PD-1/VEGF bi-specific AK112) combined with Drebuxelimab (CD73, AK119). AK112 is the first PD-1/VEGF bi-specific […]

October 17, 2022 - 2 minutesmins - By Liza Laws

News and Trends 17 Oct 2022

Way to transform Cas-9 protein into spherical nuclear acid developed

A team of researchers at U.S. Northwestern University has developed a way to transform the Cas-9 protein into a spherical nuclear acid (SNA). It can then be loaded with critical components as required to access a broad range of tissue and cell types, as well as the intracellular compartments required for gene editing. The team […]

October 17, 2022 - 4 minutesmins - By Liza Laws

News and Trends 17 Oct 2022

Italian study shows CRISPR/Cas9 deletion of Interleukin-30 reduces prostate cancer growth

Metastatic prostate cancer is a leading cause of cancer death in men worldwide. Interleukin (IL)-30, a cytokine that may perform immunomodulatory functions, promotes prostate cancer onset and development, but whether it can be a suitable therapeutic target remains to be investigated. In a new study published in the Journal of Hematology & Oncology, researchers at […]

October 17, 2022 - 2 minutesmins - By Jim Cornall

News and Trends 17 Oct 2022

PerkinElmer’s Horizon Discovery: the lowdown on base editing

PerkinElmer’s Horizon Discovery provides cell engineering tools and services for researchers in drug discovery and development. Horizon’s portfolio is focused on research reagents; screening and cell line engineering services; bioproduction cell lines; reference standards and base editing. Horizon’s base editing platform, Pin-point is a gene editing method with the ability to effect multiple single base edits […]

October 17, 2022 - 5 minutesmins - By Jim Cornall

Knowledge hub

Categories

Catalonia: A biotech hub going from strength to strength, with Barcelona at its core

Top biotech deals of February 2025

Approaches

Therapeutic areas

Grab your free report on 3D organoids and explore their future potential

These 7 biotechs are shaping the next generation of endometriosis care

R&D

BD

World biotech leaders

Connect with decision-makers and researchers worldwide for collaborative opportunities

Company

Join Us

Subscribe to our newsletter

Advertise with us

Catalonia: A biotech hub going from strength to strength, with Barcelona at its core

Top biotech deals of February 2025

Grab your free report on 3D organoids and explore their future potential

These 7 biotechs are shaping the next generation of endometriosis care

Connect with decision-makers and researchers worldwide for collaborative opportunities

Subscribe to our newsletter

Advertise with us

Cancer

Spanish research institution to use Elicera Therapeutics’ iTANK platform

Healthy volunteer study for tablet to treat brain cancer open for recruitment

Enhanc3D Genomics raises £10M to advance technology platform

License from Helmholtz Munich will enable progression of brain cancer treatment

Neobe Therapeutics breaks down tumor defenses with bacteria

Report says 20% of global cancer deaths could be avoided

Domain Therapeutics to start clinical trials of solid tumor treatment

Gene activity could help identify risk of kidney cancer spreading

Clinical trial of treatment for advanced solid tumors approved

Way to transform Cas-9 protein into spherical nuclear acid developed

Italian study shows CRISPR/Cas9 deletion of Interleukin-30 reduces prostate cancer growth

PerkinElmer’s Horizon Discovery: the lowdown on base editing

Subscribe to our newsletter to get the latest biotech news!

Catalonia: A biotech hub going from strength to strength, with Barcelona at its core

Top biotech deals of February 2025

Grab your free report on 3D organoids and explore their future potential

These 7 biotechs are shaping the next generation of endometriosis care

Connect with decision-makers and researchers worldwide for collaborative opportunities

Subscribe to our newsletter

Advertise with us

Catalonia: A biotech hub going from strength to strength, with Barcelona at its core

Top biotech deals of February 2025

Grab your free report on 3D organoids and explore their future potential

These 7 biotechs are shaping the next generation of endometriosis care

Connect with decision-makers and researchers worldwide for collaborative opportunities

Subscribe to our newsletter

Advertise with us

Subscribe to our newsletter

Get the latest biotech news directly to your inbox!

Newsletter Signup - Footer

Subscribe to our newsletter to get the latest biotech news!